COVID-19-associated Coagulopathy : Role of Vitamins D and K
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Recent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart attacks. Indeed, cardiovascular complications in COVID-19 account for 40% of mortality. Although there is no standard treatment protocol or guidelines for COVID-19, it is a common practice to use anti-inflammatory corticosteroids and anti-coagulants, especially for severe COVID-19 patients. It has also been confirmed that deficiencies of vitamin D and/or vitamin K can exacerbate premorbid cardiovascular and diabetes conditions associated with COVID-19, at least partially due to a higher incidence of coagulopathy. Here, we discuss the roles of vitamins D and K in general and in COVID-19-related coagulopathy. Moreover, the suggestion for proper supplementations of these vitamins in countering COVID-19 is provided.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 24(2023), 3 vom: 27., Seite 401-410 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Getachew, Bruk [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11103-57-4 |
|---|
| Anmerkungen: |
Date Completed 10.03.2023 Date Revised 10.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389201023666220527110455 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341605131 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341605131 | ||
| 003 | DE-627 | ||
| 005 | 20231226012151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389201023666220527110455 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341605131 | ||
| 035 | |a (NLM)35638271 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Getachew, Bruk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19-associated Coagulopathy |b Role of Vitamins D and K |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2023 | ||
| 500 | |a Date Revised 10.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Recent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart attacks. Indeed, cardiovascular complications in COVID-19 account for 40% of mortality. Although there is no standard treatment protocol or guidelines for COVID-19, it is a common practice to use anti-inflammatory corticosteroids and anti-coagulants, especially for severe COVID-19 patients. It has also been confirmed that deficiencies of vitamin D and/or vitamin K can exacerbate premorbid cardiovascular and diabetes conditions associated with COVID-19, at least partially due to a higher incidence of coagulopathy. Here, we discuss the roles of vitamins D and K in general and in COVID-19-related coagulopathy. Moreover, the suggestion for proper supplementations of these vitamins in countering COVID-19 is provided | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Thrombosis | |
| 650 | 4 | |a menaquinone | |
| 650 | 4 | |a phylloquinone | |
| 650 | 4 | |a vitamin D | |
| 650 | 7 | |a Vitamin A |2 NLM | |
| 650 | 7 | |a 11103-57-4 |2 NLM | |
| 650 | 7 | |a Vitamins |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 700 | 1 | |a Landis, Harold E |e verfasserin |4 aut | |
| 700 | 1 | |a Manaye, Kebreten F |e verfasserin |4 aut | |
| 700 | 1 | |a Tizabi, Yousef |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 24(2023), 3 vom: 27., Seite 401-410 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:3 |g day:27 |g pages:401-410 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389201023666220527110455 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 3 |b 27 |h 401-410 | ||